USA - engelsk - NLM (National Library of Medicine)

baxter healthcare corporation - cyclophosphamide (unii: 8n3dw7272p) (cyclophosphamide anhydrous - unii:6uxw23996m) - cyclophosphamide is indicated for the treatment of: cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. cyclophosphamide is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy. limitations of use: the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established. risk summary cyclophosphamide can cause fetal harm when administered to a pregnant woman based on its mechanism of action and published reports of effects in pregnant patients or animals. exposure to cyclophosphamide during pregnancy may cause fetal malformations, miscarriage, fetal growth retardation, and toxic effects in the newborn. cyclophosphamide is teratogenic and embryo-fetal toxic in mice, rats, rabbits and monkeys. if this drug is

USA - engelsk - NLM (National Library of Medicine)

baxter healthcare corporation - cyclophosphamide (unii: 8n3dw7272p) (cyclophosphamide anhydrous - unii:6uxw23996m) - cyclophosphamide is indicated for the treatment of: cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. cyclophosphamide is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy. limitations of use: the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established. pregnancy category d risk summary cyclophosphamide can cause fetal harm when administered to a pregnant woman based on its mechanism of action and published reports of effects in pregnant patients or animals. exposure to cyclophosphamide during pregnancy may cause fetal malformations, miscarriage, fetal growth retardation, and toxic effects in the newborn. cyclophosphamide is teratogenic and embryo-fetal toxic in mice, rats, rabbits and monke

USA - engelsk - NLM (National Library of Medicine)

bluepoint laboratories - cyclophosphamide (unii: 8n3dw7272p) (cyclophosphamide anhydrous - unii:6uxw23996m) - cyclophosphamide is indicated for the treatment of: cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. cyclophosphamide is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy. limitations of use: the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established. pregnancy category d risk summary cyclophosphamide can cause fetal harm when administered to a pregnant woman based on its mechanism of action and published reports of effects in pregnant patients or animals. exposure to cyclophosphamide during pregnancy may cause fetal malformations, miscarriage, fetal growth retardation, and toxic effects in the newborn. cyclophosphamide is teratogenic and embryo-fetal toxic in mice, rats, rabbits and monke

USA - engelsk - NLM (National Library of Medicine)

attix pharmaceuticals - cyclophosphamide (unii: 8n3dw7272p) (cyclophosphamide anhydrous - unii:6uxw23996m) - cyclophosphamide anhydrous 5 kg in 5 kg

Malta - engelsk - Malta Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - cyclophosphamide - powder for solution for injection/infusion - cyclophosphamide 500 mg - antineoplastic agents

Malta - engelsk - Malta Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - cyclophosphamide - powder for solution for injection/infusion - cyclophosphamide 1000 mg - antineoplastic agents

Malta - engelsk - Malta Medicines Authority

baxter healthcare limited - cyclophosphamide - powder for solution for injection - cyclophosphamide 500 mg - antineoplastic agents

Malta - engelsk - Malta Medicines Authority

baxter healthcare limited - cyclophosphamide - powder for solution for injection - cyclophosphamide 1 g - antineoplastic agents

Malta - engelsk - Malta Medicines Authority

baxter healthcare limited - cyclophosphamide - coated tablet - cyclophosphamide 50 mg - antineoplastic agents

Malta - engelsk - Malta Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - cyclophosphamide - powder for solution for infusion or injection - cyclophosphamide 500 mg - antineoplastic agents